This review is a summary of a recent speaker event on the clinical relevance of the immunological impact of long-term treatment with botulinumtoxinA.
The presentation was given by Dr Michael Hayes, Head of Department of Neurology at Concord Hospital; Prof Dr Michael Martin, Professor for Immunology at the Biomedical Research Center in Seltersberg, Germany and Dr Jürgen Frevert, Past Head of Botulinum Toxin Research at Merz Pharmaceuticals in Germany.
Please login below to download this issue (PDF)